GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) — Arcellx today announced that the first patient has been dosed with its engineered T cell therapy utilizing a novel deimmunized synthetic binding domain in the treatment of patients with relapsed and refractory multiple myeloma. This first-in-human Phase 1 trial is the first in a series of clinical trials planned for efficient, stepwise development of the Arcellx ARC-T + sparX cell therapy platform, with BCMA as an initial target.
{iframe}https://www.globenewswire.com/news-release/2020/02/28/1992599/0/en/Arcellx-Announces-First-Patient-Treated-with-T-Cell-Therapy-Utilizing-the-Company-s-Novel-Binding-Domain.html{/iframe}